Elevation Oncology, Inc. (ELEV): Price and Financial Metrics
ELEV Price/Volume Stats
| Current price | $0.71 | 52-week high | $5.83 |
| Prev. close | $0.67 | 52-week low | $0.50 |
| Day low | $0.66 | Volume | 2,287,700 |
| Day high | $0.73 | Avg. volume | 6,800,864 |
| 50-day MA | $0.64 | Dividend yield | N/A |
| 200-day MA | $1.84 | Market Cap | 42.05M |
ELEV Stock Price Chart Interactive Chart >
Elevation Oncology, Inc. (ELEV) Company Bio
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.
ELEV Price Returns
| 1-mo | 22.41% |
| 3-mo | 18.22% |
| 6-mo | -75.43% |
| 1-year | -74.82% |
| 3-year | -87.48% |
| 5-year | N/A |
| YTD | 26.20% |
| 2024 | 4.77% |
| 2023 | -43.47% |
| 2022 | -84.22% |
| 2021 | N/A |
| 2020 | N/A |
Loading social stream, please wait...